Key Highlights

● Rapport priced about $175 million of stock at $21.00 a share.

● The raise also included $150 million of convertible notes.

● Total financing was described as roughly $350 million.

● Rapport develops precision medicines for neurological disorders.

Rapport Therapeutics (NASDAQ:RAPP) tumbled after the biotech priced a stock offering at $21 a share. The company priced about $175 million of common stock at $21.00 a share, plus $25 million of pre-funded warrants, with a separate report citing $150 million of convertible notes as part of the financing. One source described the total raise as $350 million.

Reports differed on how the deal was structured and on the size of the stock's decline, but all showed a steep drop.

Why Offerings Weigh on Shares

When a company sells new shares, it increases the total number of shares outstanding, diluting existing holders since each share now represents a smaller slice of the company. Offerings are also often priced at a discount to the most recent trading price to attract buyers, which can pull the stock toward the offering level.

Convertible notes add another layer of potential dilution, since these bonds can later be exchanged for shares. For a development-stage biotech, raising money is often a necessary step to fund clinical trials and extend how long the company can operate before it needs more capital.

What Rapport Does

Rapport Therapeutics is a clinical-stage biotech focused on precision medicines for neurological disorders, aiming to develop treatments that target specific receptor complexes in the brain for more selective effects and fewer side effects than older drugs.

Its work centers on conditions such as epilepsy, and like other companies at its stage, it does not have an approved product, so its value rests on the promise of its pipeline.